MINDACT Trial: Agendia's MammoPrint Test Identifies No-Chemo Candidates

Results from the MINDACT trial show Agendia BV's MammaPrint 70-gene lab test can identify the 46% of early-stage breast cancer patients whose risk of recurrence is so low that they would be better off with surgery alone and not chemotherapy.

MINDACT (Microarray In Node-negative and one to three positive lymph node Disease may Avoid Chemo Therapy) was sponsored by the European Organisation for Research and Treatment of Cancer, Agendia, Breast...